Cargando…

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer

The long‐term efficacy of nivolumab in esophageal squamous cell carcinoma and its association with disease biomarkers are currently not well known. Therefore, we investigated the association in Japanese patients with treatment‐refractory advanced esophageal cancer who participated in an open‐label,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Ken, Doki, Yuichiro, Ura, Takashi, Hamamoto, Yasuo, Kojima, Takashi, Tsushima, Takahiro, Hironaka, Shuichi, Hara, Hiroki, Kudo, Toshihiro, Iwasa, Satoru, Muro, Kei, Yasui, Hirofumi, Minashi, Keiko, Yamaguchi, Kensei, Ohtsu, Atsushi, Kitagawa, Yuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226206/ https://www.ncbi.nlm.nih.gov/pubmed/32160365 http://dx.doi.org/10.1111/cas.14380

Ejemplares similares

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study
por: Arai, Hiroyuki, et al.
Publicado: (2019)

Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807)
por: Hironaka, Shuichi, et al.
Publicado: (2014)

Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer
por: Yokota, Tomoya, et al.
Publicado: (2016)

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
por: Takahashi, Masanobu, et al.
Publicado: (2020)

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)
por: Kato, Ken, et al.
Publicado: (2022)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy
por: Inagaki, Chiaki, et al.
Publicado: (2023)

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study
por: Yoshino, Takayuki, et al.
Publicado: (2015)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group
por: Hirata, Kenro, et al.
Publicado: (2020)

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
por: Kato, Ken, et al.
Publicado: (2018)

Nivolumab-induced interstitial lung disease in a patient with gastric cancer
por: Kimura, Akie, et al.
Publicado: (2019)

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
por: Okada, Morihito, et al.
Publicado: (2022)

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
por: Kato, Ken, et al.
Publicado: (2018)

Nutrition Support for Head and Neck Squamous Cell Carcinoma Patients Treated with Chemoradiotherapy: How Often and How Long?
por: Ishiki, Hiroto, et al.
Publicado: (2012)

Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1
por: Kitagawa, Yuko, et al.
Publicado: (2023)

Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2
por: Kitagawa, Yuko, et al.
Publicado: (2023)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2013)

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
por: Kato, K., et al.
Publicado: (2021)

A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma
por: Satake, Hironaga, et al.
Publicado: (2016)

Management of elderly patients with esophageal squamous cell cancer
por: Hamamoto, Yasuo, et al.
Publicado: (2022)

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
por: Iikura, Yusuke, et al.
Publicado: (2022)

Multidrug Resistance in Cultured Human Leukemia and Lymphoma Cell Lines Detected by a Monoclonal Antibody, MRK16
por: Ishida, Yasushi, et al.
Publicado: (1989)

A Novel Multidrug Resistance in Cultured Leukemia and Lymphoma Cells Detected by a Monoclonal Antibody to 85‐kDa Protein, MRK20
por: Ohtsu, Tomoko, et al.
Publicado: (1989)

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
por: Satoh, Taroh, et al.
Publicado: (2019)

Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer
por: Yamaguchi, Kensei, et al.
Publicado: (2022)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
por: Watanabe, Hirofumi, et al.
Publicado: (2020)

Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
por: Gannichida, Ako, et al.
Publicado: (2022)

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
por: Doi, Toshihiko, et al.
Publicado: (2018)

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
por: Sawaki, Akira, et al.
Publicado: (2011)

Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
por: Hagi, Takaomi, et al.
Publicado: (2020)

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
por: Yamaguchi, Kensei, et al.
Publicado: (2021)

Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy
por: Iwasa, Satoru, et al.
Publicado: (2020)

A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
por: Sekai, Ikue, et al.
Publicado: (2021)

Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study
por: Hosokawa, Ayumu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_go23lcf29b78fmr8anvhnkk8hh